brintellex
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 497
  • Home
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2021  |  Volume : 8  |  Issue : 2  |  Page : 77-82

Cariprazine for late-life psychiatric illness: A review on therapeutic potential and challenges


1 Department of Psychiatry, Viswabharathi Medical College, Kurnool, Andhra Pradesh, India
2 Department of Psychiatry, Varma Hospitals, Bhimavaram, Andhra Pradesh, India

Correspondence Address:
Dr. Shiva Shanker Reddy Mukku
Department of Psychiatry, Viswabharathi Medical College, Kurnool - 518 463, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jgmh.jgmh_43_21

Rights and Permissions

Clinicians often face many challenges in the pharmacological treatment of late-life psychiatric illness especially while choosing an antipsychotic drug. The choice of antipsychotic is mostly guided by the extension of evidence from the adult population and tolerability. In India, based on evidence commonly prescribed antipsychotic drugs for older adults are quetiapine (QTP) followed by olanzapine (OLZN) and risperidone. Cariprazine is a newer antipsychotic that was recently launched in India. It is a novel mechanism of action at D3 receptors is known to have antidepressant and procognitive action in addition to the antipsychotic effects which is desirable in geriatric population. It can be a potential option as an add-on drug in late-life depression in addition to the existing aripiprazole and OLZN. The treatment of late-life mania and very late-onset schizophrenia is limited by the paucity of studies, with randomized control studies done only on QTP and amisulpride, respectively. Cariprazine can be considered in late-life psychotic disorders with the evidence available from its efficacy studies in adult patients. Merits of cariprazine are favorable metabolic profile, cardiac safety, and procognitive action. Demerits include extrapyramidal symptoms and fluctuations in blood pressure. Slower titration and monitoring for akathisia are recommended. There is a need for controlled studies in older adults with cariprazine to get better informed about its efficacy and safety.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1099    
    Printed22    
    Emailed0    
    PDF Downloaded81    
    Comments [Add]    

Recommend this journal